Breast Neoplasm Malignant Female
12
4
5
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.3%
1 terminated out of 12 trials
83.3%
-3.2% vs benchmark
17%
2 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Step Count and Treatment Response in Neoadjuvant Breast Cancer
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer
Study of the Impact of DPD Activity on the Efficacy of Capecitabine
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
Use of Microporous Polysaccharide Hemispheres in Breast Cancer Patients Undergoing Mastectomy
Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)
Safety and Performance of REGENERA Breast Implant in Women Affected by Malignant Breast Lesion Treated by Lumpectomy
Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients
PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer
Interest of Touch-massage in Hospital Day Care
SBRT for Breast Cancer Oligometastases